Characterising the effect of normal brain ageing on MEG recordings: a diagnostic tool?

Alexander McMurray



Master of Science by Research
Neuroinformatics

DTC in Neuroinformatics and Computational Neuroscience
School of Informatics
University of Edinburgh
2014

Abstract

Acknowledgements

I would like to thank my supervisor, Dr Javier Escudero, for his guidance and support throughout the project and the staff of the Cognitive and Computational Neuroscience Lab, Centro de Tecnologìa Biomédica (CTB), Madrid for their kind hospitality and helpful advice.

Declaration

I declare that this thesis was composed by myself, that the work contained herein is my own except where explicitly stated otherwise in the text, and that this work has not been submitted for any other degree or professional qualification except as specified.

(Alexander McMurray)

Table of Contents

1	Inti	Introduction			
	1.1	Motivation	7		
	1.2	Hypothesis and Objectives	8		
	1.3	Results Achieved	9		
	1.4	Outline	10		
2	Bac	ekground	11		
	2.1	Alzheimer's Disease	11		
	2.2	Magnetoencephalography	13		
	2.3	Previous work	14		
3	Me	thodology	15		
	3.1	Data cleaning	15		
	3.2	Artefact Rejection	17		
	3.3	Filtering and Feature Extraction	18		
	3.4	Model Fitting	19		
	3.5	Data visualisation	21		
		3.5.1 t-Distributed Stochastic Neighbour Embedding	21		
4	Cor	nclusion and future works	23		
\mathbf{B}^{i}	iblios	graphy	24		

List of Figures

2.1	The progression of Alzheimer's Disease and the associated MMSE	
	scores. [?]	12
3.1	The artefact rejection GUI from FieldTrip	17
3.2	An example PSD taken from the data. Notice the sharp decline in	
	power at 1.5 and 40 Hz due to the bandpass filter	19
3.3	The division of the MEG channels into regions: Anterior (cyan),	
	Central (red), Left Lateral (yellow), Right Lateral (green) and Pos-	
	terior (blue) [?]	20
3.4	The MMSE score plotted against the residuals of the model, the	
	lines of best fit are plotted for each group. The black line is the	
	line of best fit for the two groups combined. The correlations are	
	very weak the r^2 statistics are 0.0146 for the AD group, 0.0168 for	
	the MCI group and 0.0060 for the two groups combined	22

Chapter 1

Introduction

1.1 Motivation

The twentieth and twenty-first centuries have seen a rapid increase in life expectancy but the consequent growth of the elderly population has led to an increasing prevalence of dementia. [?] Therefore the accurate diagnosis of Alzheimer's Disease (a leading cause of dementia) is an increasingly important problem.

Alzheimer's disease can be confirmed by post-mortem analysis of the brain for characteristic lesions but diagnosis of living patients depends upon neuroimaging and neuropsychological methods. Unfortunately incorrect diagnosis is common ranging from 10% to 30% and it is more difficult to detect earlier in the disease as the symptoms are less severe but this is also when experimental treatments are perhaps more likely to be successful. It has been noted that the lack of understanding of the normal brain ageing process remains a major challenge to accurate diagnosis but that Magnetoencephalography (MEG) remains a promising area of investigation for clinical diagnosis. [?]

The development of reliable and objective diagnostic techniques would be invaluable to improve the selection of suitable candidates for clinical trials and thus improve the chance of discovering successful early stage treatments. An analogy can be found in cancer treatment - if clinical trials were only carried out on late Stage IV cancer patients then it would be concluded that we had very few, if any, effective treatments so the correct identification of early stage patients is vital to curing the disease. Unsurprisingly, the early detection of Alzheimer's disease has become a topic of intense focus in recent years. [?]

1.2 Hypothesis and Objectives

"It is a capital mistake to theorise before one has data. Insensibly one begins to twist facts to suit theories, instead of theories to suit facts."

Arthur Conan Doyle, The Adventures of Sherlock Holmes (1892)

The hypothesis was that Alzheimer's disease effects the normal course of brain aging, and thus a model which predicted the age of a subject from the MEG recordings which was based on healthy subject would fail when applied to Alzheimer's and MCI patients. Due to the damage that Alzheimer's causes to synapses it would seem logical to believe that the healthy model would overestimate the true age of the patient due to the accelerated damage to the brain caused by Alzheimer's Disease. It is also assumed that the magnitude of error the healthy model had for a given patient would be proportional to the severity of their disease which can be measured by their scores on the Mini Mental State Examination (MMSE), a standard cognitive test used with Alzheimer's and Mild Congnitive Impairment (MCI) patients. The difference between Alzheimer's Disease and MCI will be discussed in the background section.

The model to be used is a multiple linear regression model with the age as the dependent variable and the relative powers of the different spectral bands averaged over different brain regions as the explanatory variables. The failure of the model can thus be quantified using the Root Mean Squared Error (RMSE) value, which can be estimated via bootstrap samples for the diseased patients and via cross-validation when obtaining the model from the healthy subjects. The classifier to be used will be a boosted decision trees algorithm that is robust to class imbalance (RUSBOOST). This will be explained in the section describing the methodology.

To summarise, the main objectives of the project were:

- Create a multiple linear regression model relating the relative powers of the spectral bands in the MEG recordings to the age of the subject, using healthy subjects
- See if the failure of this model in diseased patients correlates with the severity of their condition, as measured by the RMSE value and MMSE score respectively

• Attempt to distinguish between healthy and diseased subjects using a classifier

1.3 Results Achieved

Initially the results seemed optimistic as the RMSE values for the healthy, MCI and Alzheimer's patients showed that the model was less accurate when applied to diseased patients as hypothesised and that the magnitude of failure was worse for the more severely affected Alzheimer's group than for those with MCI, which was also as expected. However, the RMSE value of the model on healthy patients was still relatively high with the estimates having a mean of 14.86 years and a standard deviation of 2.68 years (note that this is the standard deviation of the sampling distribution and thus is equivalent to the standard error of the RMSE statistic).

However, subsequent projections of the data were worrying as the classes did not appear to be separable, neither by age within a class nor between classes as a whole. This implied that perhaps the relative powers would not allow us to distinguish between the healthy subjects and diseased patients, and thus the model based on them would also lack such discriminative ability.

This was corroborated by the classifier results which were no better than a 'dumb' classifier which simply predicts all subjects to be healthy irrespective of the data. However, given that the data processing pipeline from raw MEG signal to feature vector is very long and involves many variables such as how to perform the artefact detection, filtering, whether to include noisier signals etc. this study does not prove that the relative powers are unable to distinguish between the disease states.

It is possible that careful tweaking of the pipeline would result in success. However, as a preliminary study it demonstrates that such a task is likely to be difficult.

1.4 Outline

The document will be structured as follows:

- Background Discussion of the literature related to the topic and past work. Includes a brief introduction to Magnetoencephalography and Alzheimer's disease covering the relevant aspects of those fields.
- Methodology and Results Describes the work undertaken and the results obtained. Explains the processes of data cleaning, artefact rejection, feature extraction, data visualisation and attempted classification.
- Evaluation Interpreting and evaluating the results.
- Conclusion Final statements about the work and suggestions for future work.

Chapter 2

Background

2.1 Alzheimer's Disease


Alzheimer's Disease (AD) is the most common cause of dementia, its incidence increases with age and it afflicts 6% of the population aged over 65. [?] It is characterised by cognitive dysfunction (loss of memory, language difficulties etc.), psychiatric symptoms (depression, hallucinations and delusions) known as non-cognitive symptoms. Severe cases may be unable to perform basic living tasks such as eating and dressing unaided. AD is a terminal disease, with death usually resulting from an associated condition such as complications of pressure ulcers or pneumonia that can manifest following the muscle atrophy that is typical in late-stage Alzheimer's patients. [?]

Patients may become confused and aggressive. Interestingly these disruptive episodes have been shown to follow a temporal pattern, being more frequent in the late afternoon and early evening - a phenomenon known as 'sundowning'. [?] There is high comorbidity between AD and vascular disease to such an extent that the traditional distinction between AD and vascular disease as two separate diseases has been called into question. [?]

The shift from the normal cognitive decline expected with healthy aging to preclinical dementia appears to be a gradual, continuous transition. The prodromal stage of AD is referred to as Mild Cognitive Impairment (MCI), it is characterised by memory impairments that would not be expected due to normal age-related related cognitive decline in the individual given their age and educational history (both are strong correlates for memory function). The status of MCI as a legitimate prodromal stage of AD rather than the mere medicalisation

of normal decline is supported by the fact that patients diagnosed with MCI are 15 times more likely to develop AD than those without a history of MCI. [?]

Diagnosis is typically performed on the basis of cognitive and memory tests the most common being the Mini Mental State Examination (MMSE) (see Figure 2.1). Neuroimaging can aid diagnosis but no single modality has been proven as an accurate screening test. Neuroimaging used in embination with psychological testing outperforms either alone. [?]



Mild cognitive impairment: Complaints of memory loss, intact activities of daily living, no evidence of Alzheimer's disease

Mild Alzheimer's disease: Forgetfulness, short term memory loss, repetitive questions, hobbies, interests lost, impaired activities of daily living

Moderate Alzheimer's disease: Progression of cognitive deficits, dysexecutive syndrome, further impaired activities of daily living, transitions in care, emergence of behavioural and psychological symptoms of dementia

Severe Alzheimer's disease: Agitation, altered sleep patterns, assistance required in dressing, feeding, bathing, established behavioural and psychological symptoms of dementia

Very severe Alzheimer's disease: Bedbound, no speech, incontinent, basic psychomotor skills

Figure 2.1: The progression of Alzheimer's Disease and the associated MMSE scores. [?]

Although it is true that the there has been comparatively little progress in the search for an Alzheimer's cure compared to the improvement in diagnostic techniques the early diagnosis of MCI can help prevent misdiagnosis of AD and the selection of medical trial candidates. Furthermore, in the future it may allow preventative treatment to halt the progression or onset of the disease - given the modest success of late-stage intervention and the search for a cure there has been a great increase in interest concerning preventative treatment of Alzheimer's disease. [?]

2.2 Magnetoencephalography

Magnetoencephalography (MEG) is a functional neuroimaging technique that measures the brain activity directly via measurement of the magnetic fields created by electrical currents at the synapses. This is a difficult task as the magnetic fields are extremely weak $(10 - 10^3 \text{ fT})$ and thus requires the use of expensive and complicated neuromagnetometers which achieve their high sensitivity by the use of Superconducting Quantum Interference Devices (SQUIDs). Although it is worth mentioning that the first MEG recordings took place in the late 1960's before SQUIDs were available, instead using an induction coil magnetometer consisting of 2 million turns of copper wound about a ferrite core. [?]

Furthermore the weakness of the magnetic fields relative to ambient magnetic noise (10⁸ fT) requires shielding the laboratory to reduce noise. The magnetic field due to an electric current is described by Ampère's Law and the direction can be easily determined by the right hand rule. As the magnetic field is orthogonal to the current, MEG is sensitive to the tangential component of the synaptic currents and therefore is most sensitive to pyramidal neurons near the cortical surface as pyramidal neurons have most of their currents tangential to the cortical surface and MEG is generally not sensitive to deep brain regions (although some studies have shown this may not always be the case [?]).

Despite these problems of MEG it has several advantages over other methods:

- It is non-invasive and has a high temporal resolution
- Magnetic fields unlike electric fields in Electroencephalography (EEG) are not impeded by the skull, scalp etc.
- Unlike EEG it does not require a reference signal allowing for easier source localisation [?]
- It is a direct measurement, unlike many methods such as fMRI and fNIRS which use cerebral blood flow as a proxy for neural activity

MEG recordings are often combined with anatomical MRI to enable accurate source localisation. The data processing requires the removal of artefacts which can be divided into three kinds: System related artefacts (Superconducting Quantum Interference Device (SQUID) jumps, nosiy/saturated channels etc.), external artefacts (due to power lines, mains AC etc.), physiological artefacts (due

to eye movements, cardiac/muscle activity, head movement etc.). [?] The visual inspection of raw data and power spectra is highly recommended although often automated/semi-automated approaches will have to be used due to the large volumes of data recorded. The way these challenges were handled in the present work will be discussed in the Methodology chapter.

2.3 Previous work

MEG has been used to investigate a wide range of brain disorders including Alzheimer's, Schizophrenia, Major Depressive Disorder and Autism. Techniques include synchrony and coherence studies (due to its high temporal resolution), Spectral ratios (the ratios of relative powers of the different frequency bands) and non-linear techniques such as complexity analysis. [?]

As a result of these studies it was discovered that many brain disorders including Alzheimer's, depression, attention-deficit hyperactivity disorder and schizophrenia result in a change in the effect of ageing on brain activity as compared to healthy controls - this was described as a 'rupture' in the normal evolution of the neural activity. [?]

Previous analysis on the dataset intended for use in this study found that brain oscillatory complexity (as quantified by the Lempel-Ziv Complexity algorithm) had a quadratic relationship with age. [?] It was also discovered that spectral properties followed a similar quadratic relationship. [?]

Chapter 3

Methodology

3.1 Data cleaning

The original proposal did not allocate a great deal of time (2-3 weeks) to data cleaning (dealing with any problems the data may have and loading it into a format amenable to further processing) this turned out to be more difficult than expected and as such took significantly longer (4-5 weeks, including a visit to an MEG laboratory to learn more about the data acquisition methods and processing techniques - which proved invaluable).

Most of the data for the healthy control patients was in the same format of a text file consisting of one column per MEG channel and one column for the time vector with each sample being a separate row. However some of the subjects shared the format of the Alzheimer's and MCI patients in which each the data for each channel (and the time vector) were contained within separate folders. Furthermore, some of the subjects had their data in different units as all the data had been multiplied by a factor of 1×10^5 due to different conventions between the Spanish and English versions of Microsoft Excel which had been used to manipulate the raw data several years ago.

Eleven of the data files were corrupted. Initially it seemed that that it would be possible to still use these subjects - using interpolation to deal with the missing data and rejecting the epochs where the interpolation was used to remove any effect upon the final data. However this ended up being very time-consuming as some of the data had multiple corruptions and some was so corrupted that even attempted to partially load the data failed. Therefore as the eleven subjects represented less than 5% of the total 233 healthy controls it was decided that it

wasn't worth the time it would take to recover the data.

Almost all of the data had been downsampled at acquistion, however for reasons that remain unknown, three uncorrupted subjects and one of the corrupted ones had not been downsampled. As the desired sampling rate was known however, it was easy to downsample these subjects using the decimate function in MATLAB, this automatically filters the data first to satisfy the Nyquist criterion and avoid aliasing.

The Nyquist criterion in this context refers to the requirement that the highest frequency contained in the signal is less than half of the sampling rate. If this is not the case then aliasing will occur in which the frequency of the sampled signal does not match the frequency of the original continuous signal. This loss of information means that accurate reconstruction of the original signal is impossible. Thus prior to downsampling (reducing the sample rate), the signal is first passed through a low-pass filter with a threshold at the Nyquist frequency $(\frac{1}{2})$ of the new downsampled sampling rate) so that aliasing does not occur. [?] It was decided to use the FieldTrip MATLAB library [?] designed for EEG/MEG analysis. This would make the artefact rejection easier to perform in a more rigorous and standardised manner. Unfortunately the FieldTrip library expected the data in the format output by the original MEG machine and not the format in which we had recieved the data. After many attempts to load the data it appeared it would not be successful and so we produced our own artefact rejection scripts in MATLAB. This proved to be unnecessary as following a discussion with the Cognitive and Computational Neuroscience group at the Centro de Tecnología Biomédica (CTB), Madrid we discovered that it was possible to 'trick' Fieldtrip into loading the data provided one could provide a data header file with correct sensor information from an actual MEG machine. As the group could provide us with such a file we were then able to successfully load the data into FieldTrip and thus use it for the artefact rejection and signal processing.

The age of the subjects (and MMSE scores for the diseased patients) were stored across various different Excel spreadsheets. As these had been compiled by hand there were some typos in the filenames and differing conventions that made it impossible to fully automate the process of extracting the data into MATLAB. However it was possible to semi-automate it such that only the filenames that didn't match an entry in the spreadsheet required further inspection, reducing the number of files to check from 220 to around 40 and thus significantly reducing

the time required.

3.2 Artefact Rejection

The artefact rejection process was performed in FieldTrip as mentioned previously. It is performed by computing the z-score for each point in time for each channel:

$$z_{\rm ch, t} = \frac{x_{\rm ch, t} - \mu_{\rm ch}}{\sigma_{\rm ch}} \tag{3.1}$$

where $\mu_{\rm ch}$ is the mean of the channel signal and $\sigma_{\rm ch}$ is the standard deviation of the channel signal whilst $x_{\rm ch, t}$ is the value of the signal in a certain channel at a certain time.

The z-score is accumulated across all channels:

$$zsum_t = \sum_{ch=1}^{148} = \frac{z_{\text{ch, t}}}{\sqrt{148}}$$
 (3.2)

where the number of channels is 148. This accumulated z-score value is compared to a threshold set by the user and if it exceeds the threshold then that epoch is rejected across all channels.




Figure 3.1: The artefact rejection GUI from FieldTrip.

Although it is possible to automate the entire process by setting a single threshold the differing noise levels between subjects meant that setting the same threshold for each subject resulted in extremely poor results. Therefore it was conducted using the manual Graphical User Interface (GUI) as shown in Figure 3.1. This was quite a time-consuming process and took perhaps eight hours of solid work to process all the signals. However this approach which thresholds against the accumulated z-score was still much faster than inspecting each epoch for each channel for each patient. As there was an average of 60 5-second epochs per subject with 148 MEG channels and 278 subjects (combined total of healthy, MCI and AD) and so traditional visual inspection would have taken far too long as it would require the inspection of almost 2.5 million individual epochs.

3.3 Filtering and Feature Extraction

When the data was loaded into FieldTrip an 560th order Finite Impulse Response (FIR) filter with a Hamming window and a bandpass of 1.5 to 40Hz was applied as used by previous groups. [?]. The filter was applied to the whole signal rather than to each epoch separately to minimise edge effects (so the edge effects just occur at the first and last epochs, which can be discarded). The power spectral densities for each 5-second epoch were then obtained via Welch's method [?] favoured for its noise reduction properties. See Figure 3.2 for an example PSD obtained from the dataset.

The relative powers were then calculated for each spectral band of interest (the conventional frequency bands associated with neural oscillations): delta (1.5-4 Hz), theta (4-8 Hz), alpha (8-13 Hz), the beta band was split into two sections - beta1 (13-19 Hz) and beta2 (19-30 Hz). The final band of interest is gamma (30-40 Hz). These are the same selection of bands used by previous groups. [?].

The relative powers are calculated by normalising the power spectral density (PSD) by the power contained in the total bandpass [?]:

$$PSD_n(f) = \frac{PSD(f)}{\underset{f=1}{\sum} PSD(f)}$$
(3.3)

and then computing the relative powers for each band from this normalised PSD:

$$RP = \sum_{f=f_{\text{low}}}^{f_{\text{high}}} PSD_n(f) \tag{3.4}$$

where f_{high} and f_{low} are the high and low cut-offs for the band respectively.




Figure 3.2: An example PSD taken from the data. Notice the sharp decline in power at 1.5 and 40 Hz due to the bandpass filter.

The relative powers were averaged over all accepted epochs and the channels were averaged into five brain regions (Central, Anterior, Left Lateral, Posterior, Right Lateral) shown in Figure 3.3

For some of the visualisations these regions were averaged over to reduce the number of features and thus the dimensionality of the data. This will be explicitly stated when the relevant visualisations are discussed. Averaging over the regions (i.e. averaging the relative powers over all channels) was also performed in previous studies [?] so it is reasonable to assume that there was not too much information lost.

3.4 Model Fitting

The features were fit with a multiple linear regression model:

$$y = b_0 + b_1 x_1 + b_2 x_2 \dots + b_{30} x_{30} \tag{3.5}$$

where y is the dependent variable, the age of the subject, and x_i are the explanatory variables (the relative powers of the different spectral bands in the different regions). The b_i values are the regression coefficients, including the coefficient of




Figure 3.3: The division of the MEG channels into regions: Anterior (cyan), Central (red), Left Lateral (yellow), Right Lateral (green) and Posterior (blue) [?]

the bias column of ones which was added to the feature vector in order to obtain the y-intercept of the fit.

The final model was obtained by a form of weighted model averaging. Tenfold cross-validation was used to obtain ten different models (i.e. ten sets of regression coefficients). Tenfold cross-validation involves partitioning the data into ten sets and training the model on 9 whilst using the remaining one as the test set, for all ten combinations. This prevents unrealistically optimistic error reports due to using the training data as a test set and thus provides a reasonable expectation of how well the model will generalise to unseen data. Furthermore, it is a natural means to obtain a number of models which can be used in model averaging to improve performance.

The model averaging was performed by calculating the weighted average of the regression coefficients from each model, weighted by the reciprocal of the root mean squared error (RMSE) value of each model:

$$\vec{b}_{avg} = \frac{\sum_{i=1}^{10} \vec{w}_i \vec{b}_i}{\sum_{i=1}^{10} \vec{w}_i}$$
(3.6)

where
$$\vec{w_i} = \frac{1}{\text{RMSE}_i}$$
.

Bootstrapping (i.e. sampling with replacement) [?] was used to obtain an estimate of the RMSE of the averaged model on the Alzheimer's and MCI datasets. The estimates used 1000 bootstrap iterations which allows for an accurate estimation of the standard deviation of the sample distribution of the RMSE statistic (i.e. the standard error of the true distribution of the RMSE statistic). Each bootstrap set contained as many data points as in the set as a whole (so the Alzheimer's bootstraps each consisted of 39 samples and the MCI ones of 18 samples) - this is known as the 0.632 bootstrap as each set will contain 63.2% of the unique data samples on average. It is the most common bootstrapping method. [?]

Dataset	RMSE Mean	RMSE Sample standard error
Healthy	14.86	2.68
MCI	22.72	3.03
AD	26.93	2.65

Table 3.1: The RMSE values obtained on the model from each of the datasets.

The residuals of the model fit demonstrate the difference between the predicted age of the model and the subject's actual age. These were plotted against the subjects MMSE scores in Figure ?? (MMSE data only available for Alzheimer's and MCI patients, not healthy subjects).

3.5 Data visualisation

As the data consisted of 30 features (6 spectral bands \times 5 sensor regions) it cannot easily be visualised in a two-dimensional space amenable for printing, however it is possible to project the to a lower dimensional space or to display the relationships between feature values in a different manner (in the case of the parallel co-ordinate plot).

3.5.1 t-Distributed Stochastic Neighbour Embedding

[?]




Figure 3.4: The MMSE score plotted against the residuals of the model, the lines of best fit are plotted for each group. The black line is the line of best fit for the two groups combined. The correlations are very weak the r^2 statistics are 0.0146 for the AD group, 0.0168 for the MCI group and 0.0060 for the two groups combined

Chapter 4 Conclusion and future works

Bibliography